This document is scheduled to be published in the Federal Register on 03/09/2018 and available online at https://federalregister.gov/d/2018-04804, and on FDsys.gov

**BILLING CODE 4140-01-P** 

DEPARTMENT OF HEALTH AND HUMAN SERVICES

**National Institutes of Health** 

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby

given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions

could disclose confidential trade secrets or commercial property such as patentable material, and

personal information concerning individuals associated with the grant applications, the

disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Cutting-Edge Basic Research Awards (CEBRA) (R21)

Date: March 20, 2018

Time: 12:00 PM to 8:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Virtual Meeting)

1

Contact Person: Susan O. McGuire, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS 6001 Executive Blvd., Room 4245

Rockville, MD 20852

(301) 827-5817

mcguire so@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Development of a Device to Objectively Measure Pain

(R41/R42/R43/R44)

Date: March 29, 2018

Time: 9:00 AM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

Contact Person: Julia Berzhanskaya, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4234, MSC 9550

Bethesda, MD 20892

301-827-5840

julia.berzhanskaya@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

HIV-associated Neuropathic Pain and Opioid Interaction (R01)

Date: March 29, 2018

Time: 11:00 AM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4234, MSC 9550

Bethesda, MD 20892

301-827-5840

julia.berzhanskaya@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: March 6, 2018.

## Natasha M. Copeland,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2018-04804 Filed: 3/8/2018 8:45 am; Publication Date: 3/9/2018]